Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosi...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF
Awduron Eraill:	BSH Committee
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	Wiley 2023

Eitemau Tebyg

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline
gan: McMullin, M, et al.
Cyhoeddwyd: (2018)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
gan: McMullin, M, et al.
Cyhoeddwyd: (2018)

Allogeneic stem cell transplantation for myelofibrosis in 2012.
gan: McLornan, D, et al.
Cyhoeddwyd: (2012)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
gan: Reilly, J, et al.
Cyhoeddwyd: (2014)

Guideline for the diagnosis and management of myelofibrosis.
gan: Reilly, J, et al.
Cyhoeddwyd: (2012)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
gan: Bassiony S, et al.
Cyhoeddwyd: (2020-09-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
gan: Verstovsek, S, et al.
Cyhoeddwyd: (2021)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
gan: P. Harrington, et al.
Cyhoeddwyd: (2022-06-01)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
gan: Mead, AJ, et al.
Cyhoeddwyd: (2022)

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm
gan: Salisbury, RA, et al.
Cyhoeddwyd: (2021)

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
gan: Mclornan, D, et al.
Cyhoeddwyd: (2012)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
gan: Mesa, RA, et al.
Cyhoeddwyd: (2023)

Mutational spectrum defines primary and secondary myelofibrosis
gan: Ken I. Mills, et al.
Cyhoeddwyd: (2014-01-01)

Guideline for the diagnosis and management of myelofibrosis
gan: Reilly, J, et al.
Cyhoeddwyd: (2012)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
gan: Reilly, J, et al.
Cyhoeddwyd: (2014)

Low-dose thalidomide in myelofibrosis
gan: Robert Weinkove, et al.
Cyhoeddwyd: (2008-07-01)

A retrospective real world evidence study to review the current treatment pathways for myelofibrosis from across the United Kingdom (the REALISM UK study)
gan: Mead, A, et al.
Cyhoeddwyd: (2019)

Guideline for the investigation and management of eosinophilia
gan: Butt, N, et al.
Cyhoeddwyd: (2017)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
gan: Donal P. McLornan, et al.
Cyhoeddwyd: (2019-04-01)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
gan: Stephen T. Oh, et al.
Cyhoeddwyd: (2024-02-01)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
gan: Ruben A. Mesa, et al.
Cyhoeddwyd: (2023-05-01)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
gan: Ruben A. Mesa, et al.
Cyhoeddwyd: (2023-11-01)

Feasibility of recruitment of patients withMyeloproliferative Neoplasms into the TAPfunded TAMARIN study
gan: Harrison, C, et al.
Cyhoeddwyd: (2018)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
gan: McIlroy, G, et al.
Cyhoeddwyd: (2025)

Equivalence of BCSH and WHO diagnostic criteria for ET
gan: Harrison, C, et al.
Cyhoeddwyd: (2016)

The soldier and the post-conflict state
gan: McMullin, J, et al.
Cyhoeddwyd: (2006)

The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders
gan: Cross, NCP, et al.
Cyhoeddwyd: (2021)

Practical management of patients with myelofibrosis receiving ruxolitinib.
gan: Harrison, C, et al.
Cyhoeddwyd: (2013)

Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial
gan: McPherson, S, et al.
Cyhoeddwyd: (2018)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
gan: Adam J. Mead, et al.
Cyhoeddwyd: (2022-03-01)

Intravesical recurrence of chromophobe renal cell carcinoma
gan: Niall P. Kelly, et al.
Cyhoeddwyd: (2023-09-01)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
gan: Psaila, B, et al.
Cyhoeddwyd: (2017)

In utero origin of myelofibrosis presenting in adult monozygotic twins
gan: Sousos, N, et al.
Cyhoeddwyd: (2022)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
gan: Graham McIlroy, et al.
Cyhoeddwyd: (2025-01-01)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
gan: A. Vannucchi, et al.
Cyhoeddwyd: (2022-06-01)

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
gan: Chowdhury, O, et al.
Cyhoeddwyd: (2018)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
gan: Sousos, N, et al.
Cyhoeddwyd: (2020)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
gan: Greenfield, G, et al.
Cyhoeddwyd: (2020)

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
gan: F. Passamonti, et al.
Cyhoeddwyd: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
gan: Butt, N, et al.
Cyhoeddwyd: (2019)